<DOC>
	<DOCNO>NCT00540241</DOCNO>
	<brief_summary>The primary research objective observational study pretreated patient NSCLC Stage IIIa/b Stage IV evaluate patient ' Karnofsky Index ( KI ) second cycle second-line treatment single agent pemetrexed real life setting , evaluate factor potentially influence performance status term KI , i.e . frequency use concomitant medication , particular analgesic , folic acid , Vitamin B12 , antiemetic , medication diarrhea ; document patient diary ( day use per week ) physician .</brief_summary>
	<brief_title>Performance Status During Treatment With Pemetrexed Patients With NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Are 18 year age old Have NSCLC , Stage IIIa/b IV , amenable curative therapy Have one prior chemotherapy regimen cytotoxic agent treatment NSCLC ( patient adjuvant neoadjuvant regimen also eligible . However , patient one prior cytotoxic chemotherapy follow targeted agent erlotinib eligible target agent would regard secondline treatment ) Are initiate secondline treatment NSCLC pemetrexed Have fully inform give write consent use data . Have receive prior treatment pemetrexed Are participate study include administration investigational drug procedure entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>